MIS-C Study | Centers for Disease Control and Prevention | Rainmakers Strategic Solutions

Rainmakers Awarded Centers for Disease Control and Prevention Contract to Study MIS-C In Children

Rainmakers Strategic Solutions LLC (Rainmakers) was awarded the Multisystem Inflammatory Syndrome in Children (MIS-C) Phenotype Initiative contract from the Centers for Disease Control and Prevention (CDC). 

The goal of the Initiative is to characterize the phenotype of MIS-C and compare the findings to clinical presentations of Kawasaki Disease, Acute COVID-19 in children, and Toxic Shock Syndrome. The comparison would allow for clinical distinction between these conditions and address gaps in knowledge of MIS-C. The study will be conducted in collaboration with four children’s hospitals around the country.

“Understanding MIS-C and COVID-19 in children is critical to the care of our nation’s seriously ill children. We look forward to supporting the CDC and childrens’ hospitals in bringing important clinical guidance to the provider community.”

Denise Rainey, President & CEO of Rainmakers Strategic Solutions

Rainmakers will provide program management support to the CDC and hospitals through facilitating protocols and data sharing arrangements, working with hospitals in identifying case abstraction and blood sample volumes, and tracking case abstraction and blood sample data collection and testing completions to enable efficient study execution and distribution of results to the provider community. Given the urgent need to understand MIS-C and COVID-19 for better provision of clinical care to the nation’s children, the contract is on an accelerated timeline with results expected in mid-2021.

Share This

Scroll to Top